

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 12207-009-999	APPLICATION NO. 09/920,033
	APPLICANT Crooke et al.	
	FILING DATE August 1, 2001	ART UNIT 1633

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	5,801,154	09/01/98	Baracchini et al.	
	A02	6,949,367 B1	09/27/05	Dempsy et al.	
	A03	2003/0087853 A1	05/08/03	Crooke et al.	
	A04	2003/0215943 A1	11/20/03	Crooke et al.	
	A05	2004/0214325 A1	10/28/04	Crooke et al.	
	A06	2004/0241651 A1	12/02/04	Olek et al.	
	A07	2005/0009088 A1	01/13/05	Crooke et al.	
	A08	2005/0287558 A1	12/29/05	Crooke et al.	
	A09	2006/0009410 A1	01/12/06	Crooke et al.	
	A10	2006/0035858 A1	02/16/06	Geary et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	WO 1998/032846 A3	07/30/98	Ribozyme Pharmaceuticals, Inc.		
	B02	WO 2001/077384 A3	10/18/01	Epigenomics AG		
	B03	WO 2002/026768 A3	04/04/02	Genaissance Pharmaceuticals, Inc.		
	B04	WO 2003/011887 A3	02/13/03	Isis Pharmaceuticals, Inc.		
	B05	WO 2003/074723 A3	09/12/03	Ravgen Inc.		
	B06	WO 2003/097662 A1	11/27/03	Isis Pharmaceuticals, Inc.		
	B07	WO 2004/044181 A3	05/27/04	Isis Pharm.		
	B08	WO 2005/049621 A1	06/02/05	Isis Pharm.		

NON PATENT LITERATURE DOCUMENTS


*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	CROOKE, S. T., "Basic Principles of Antisense Therapeutics," <i>Antisense Research and Application</i> (1998) Springer-Verlag Press, Berlin, pp. 1-50.	
	C02	EMBL Accession No. L27195, January 6, 1994.	
	C03	GRAHAM, M. J. et al., "Inhibition of ApoB-100 as a Therapeutic Strategy for the Treatment of Hyperlipidemias," <i>AHA Abstract</i> (2002) ID: 548.	

LAI-2911758v1

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(attach several sheets if necessary)

ATTY. DOCKET NO.

12207-009-999

APPLICATION NO.

09/920,033

APPLICANT

Crooke et al.

FILING DATE

August 1, 2001

ART UNIT

1633

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C04	HUANG, L.-S. et al., "Hypobetalipoproteinemia due to an apolipoprotein B gene exon 21 deletion derived by Alu-Alu recombination," <i>J. Biol. Chem.</i> (1989) 264(19):11394-11400.	
	C05	JEN, K.-Y. et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> (2000) 18:307-319.	
	C06	LATORRA, D. et al., "Enhanced Allele-Specific PCR Discrimination in SNP Genotyping Using 3' Locked Nucleic Acid (LNA) Primers," <i>Hum. Mutat.</i> (2003) 22:79-85.	
	C07	MA, D. D. F. et al., "Synthetic oligonucleotides as therapeutics: the coming of age," <i>Biotechnology Annual Review</i> (2000) 5:155-196.	
	C08	PETERSEN, M. et al., "Locked Nucleic Acid (LNA) Recognition of RNA: NMR Solution Structures of LNA:RNA Hybrids," <i>J. Am. Chem. Soc.</i> (2002) 124(21):5974-5982.	
	C09	SIMEONOV, A. et al., "Single nucleotide polymorphism genotyping using short, fluorescently labeled locked nucleic acid (LNA) probes and fluorescence polarization detection," <i>Nucleic Acids. Res.</i> (2002) 30(17):e91.	
	C10	SKRAPARI, L. et al., "Glibenclamide improves postprandial hypertriglyceridaemia in Type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels," <i>Diabetic Med.</i> (2001) 18:781-785.	

LAI-2911758v1

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.